Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIF001 in Healthy Subjects and in a Patient Cohort With Epilepsy
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
100 Clinical Results associated with Kang Xu Sheng Wu Ke Ji ( Shen Zhen ) You Xian Gong Si
0 Patents (Medical) associated with Kang Xu Sheng Wu Ke Ji ( Shen Zhen ) You Xian Gong Si
100 Deals associated with Kang Xu Sheng Wu Ke Ji ( Shen Zhen ) You Xian Gong Si
100 Translational Medicine associated with Kang Xu Sheng Wu Ke Ji ( Shen Zhen ) You Xian Gong Si